The GLP-1 market in 2026 is split between two fundamentally different products: brand-name FDA-approved medications (Wegovy, Zepbound, Ozempic, Mounjaro) and compounded versions produced by 503A and 503B pharmacies. The price difference is dramatic — but so are the regulatory, safety, and availability considerations.
This guide breaks down exactly what you're getting with each option, what the real risks are, and how the FDA's April 2026 regulatory proposal changes the calculus.
The Price Gap
| Medication | Brand-Name (List) | Brand-Name (NovoCare Self-Pay) | Compounded (Typical) |
|---|---|---|---|
| Semaglutide (injectable) | ~$1,349/mo | $199–$399/mo (pen) | $130–$300/mo |
| Semaglutide (oral) | ~$1,349/mo | $149/mo (1.5 & 4mg pill) | $150–$250/mo |
| Tirzepatide (injectable) | ~$1,060/mo | N/A | $149–$350/mo |
The standout: Novo Nordisk's NovoCare program currently prices oral Wegovy tablets at $149/mo for 1.5mg and 4mg doses (promotional through August 2026). This brings brand-name semaglutide into the same price range as many compounded options for the first time.
What "Compounded" Actually Means
Compounded GLP-1 medications use the same active pharmaceutical ingredient (semaglutide or tirzepatide) as brand-name products but are mixed by compounding pharmacies rather than manufactured by Novo Nordisk or Eli Lilly. They come in different forms: injectable vials, sublingual drops, and oral tablets.
Compounded medications are regulated differently than brand-name drugs. Two types of pharmacies produce them:
- 503A pharmacies — traditional compounding pharmacies that fill individual prescriptions. Regulated primarily by state boards of pharmacy.
- 503B outsourcing facilities — larger-scale operations that can produce compounded medications without patient-specific prescriptions. Subject to FDA oversight and current good manufacturing practice (cGMP) requirements.
Both types are legal but operate under different regulatory frameworks. Neither produces "generic" semaglutide — there are no FDA-approved generics of these medications yet.
The FDA's April 2026 Proposal: What Changed
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This is a major regulatory development that affects 503B outsourcing facilities specifically.
Key details:
- The drug shortages that originally allowed widespread compounding were resolved — semaglutide in February 2025, tirzepatide in late 2024
- The FDA found "no clinical need" for outsourcing facilities to compound these medications from bulk substances
- If finalized, 503B facilities would lose authorization to produce compounded semaglutide and tirzepatide
- 503A patient-specific compounding operates under a separate legal framework and is not directly affected by this proposal — though FDA has been constraining 503A activities through other mechanisms
- Public comment period runs through June 29, 2026
The FDA also cited safety data: over 455 adverse event reports linked to compounded semaglutide and over 320 for compounded tirzepatide, many involving dosing errors from multidose vials.
Safety Comparison
| Factor | Brand-Name | Compounded |
|---|---|---|
| FDA-approved | Yes — full clinical trial program | No — compounded meds have a different regulatory pathway |
| Manufacturing oversight | FDA cGMP, rigorous quality control | 503B: FDA-inspected. 503A: state board oversight |
| Dosing format | Pre-filled pens (precise dosing) | Multidose vials (patient measures dose) |
| Adverse events reported | Established side effect profile from trials | 455+ semaglutide and 320+ tirzepatide adverse reports (FDA data) |
| Counterfeiting risk | Low — established supply chain | Higher — FDA has flagged counterfeit products online |
Who Should Choose Brand-Name
- Patients with commercial insurance that covers Wegovy or Zepbound (copay as low as $25/mo)
- Patients who want FDA-approved products with established clinical trial backing
- Patients uncomfortable with self-measuring doses from multidose vials
- Anyone who qualifies for NovoCare oral Wegovy pricing ($149/mo for 1.5mg and 4mg)
Sesame Care
Who Should Consider Compounded
- Uninsured patients for whom brand-name pricing (even with discounts) remains too high
- Patients who want tirzepatide at lower cost (no brand-name self-pay discount comparable to NovoCare for Zepbound)
- Patients who prefer format flexibility (sublingual, different concentrations)
- Patients who understand and accept the different regulatory status
Oak Longevity
BB Health+
Yucca Health
See the full provider comparison with current pricing
Compare All Providers →Sources
- FDA Press Release. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." April 30, 2026.
- Federal Register Notice, 91 Fed. Reg. 23431 (May 1, 2026). "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B."
- Pharmacy Times. "FDA Moves to Permanently Close the Door on Compounded GLP-1s." May 2026.
- NovoCare pricing: Wegovy oral tablet $149/mo for 1.5mg and 4mg (promo through Aug 31, 2026). Wegovy pen $199–$399/mo self-pay.
- FDA adverse event data: 455+ reports for compounded semaglutide, 320+ for compounded tirzepatide as of early 2025.
Affiliate Disclosure: Some links on this page are affiliate links and may generate compensation. This does not influence our editorial content.